Retatrutide (GLP-1 | GIP | Glucagon)

Retatrutide is a novel multi-receptor agonist targeting GLP-1, GIP, and glucagon receptors, studied for the treatment of obesity and metabolic disorders. It promotes weight loss by enhancing energy expenditure, reducing appetite, and improving insulin sensitivity. Early clinical trials have shown promising results, with significant reductions in mass and improvements in glycemic control, positioning Retatrutide as a potential breakthrough studied peptide.

The chemical properties below represent the Retatrutide base (2381089-83-2), whereas most commonly, the acetate is the fully prepared form of Retatrutide (LY3437943), which is the product Modern Peptides offers.